Last reviewed · How we verify

Nutriflex Omega special + Oxepa

B. Braun Melsungen AG · Phase 3 active Small molecule

Nutriflex Omega special + Oxepa is a parenteral nutrition formulation that provides essential fatty acids, amino acids, and micronutrients to support metabolic function and reduce inflammatory markers in critically ill patients.

Nutriflex Omega special + Oxepa is a parenteral nutrition formulation that provides essential fatty acids, amino acids, and micronutrients to support metabolic function and reduce inflammatory markers in critically ill patients. Used for Nutritional support in critically ill patients, Acute respiratory distress syndrome (ARDS), Sepsis and systemic inflammatory response.

At a glance

Generic nameNutriflex Omega special + Oxepa
SponsorB. Braun Melsungen AG
Drug classParenteral nutrition formulation
ModalitySmall molecule
Therapeutic areaCritical Care / Intensive Care Medicine
PhasePhase 3

Mechanism of action

Nutriflex Omega special is a lipid emulsion-based parenteral nutrition containing omega-3 and omega-6 polyunsaturated fatty acids designed to support immune function and reduce inflammation. Oxepa is an enteral/parenteral nutrition product enriched with eicosapentaenoic acid (EPA), gamma-linolenic acid (GLA), and antioxidants to modulate the inflammatory response in acute respiratory distress syndrome and critical illness.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: